Inhibition Of Sodium-glucose Transport Protein As A Therapeutic Option In The Patients With Transthyretin Cardiac Amyloidosis

Sana Riaz,Ashwin Pillai,Ina Lico,Maciej Tysarowski,Ayesha Shaik,Sabeena Arora,Abhishek Jaiswal

DOI: https://doi.org/10.1016/j.cardfail.2023.10.147

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction Patients with transthyretin cardiac amyloidosis (ATTR-CA) and heart failure do not tolerate beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors due to side effects and the efficacy of these agents remains uncertain in this patient population. Sodium-glucose transporter 2 inhibitors (SGLT2i) have significantly improved clinical outcomes in patients with heart failure (irrespective of ejection fraction) with few side effects. However, there remains a lack of data on the safety and tolerability of SGLT2i in patients with ATTR-CA. Hypothesis This observational study describes the tolerability and safety of SGLT2i in patients with ATTR-CA and heart failure. Methods A single-center retrospective observation of consecutive adult patients with ATTR-CA initiated on SGLT2i from January 2020-March 2023. Results Our study involved 53 patients with ATTR CA (74% Wild-Type); mean age 81 years (SD ± 8), 77% white, 72% men, 32% had diabetes mellitus (DM), and 51% with at least stage 3 chronic kidney disease with a mean glomerular filtration rate of 58 mL/min/1.73m (SD ±18). The median left ventricular ejection fraction (LVEF) was 50% (IQR 36, 55). Of the 53 patients, 28% had an LVEF ≤ 40%, and 2% required inotrope, which was initiated at the same time as SGLT2i. In our study, 89% received empagliflozin and the rest dapagliflozin. The mean duration of treatment with SGLT2i was 19 months (SD ± 9). While on treatment with SGLT2i, 92% of patients were also on guideline-directed medical therapy (GDMT) with at least one agent. The most common GDMT used with SGLT2i was mineralocorticoid receptor antagonist (87%). Following initiation of SGLT2i, acute kidney injury (an increase in serum creatinine ≥ 0.3 mg/dL) developed in 3.8% (2) and urinary tract infection in 6% (3). New orthostatic hypotension was not noted in any patient following the initiation of SGLT2i. SGLT2i was discontinued in 6% (3) patients: following complicated UTI (1), discontinued by the patient (1), and transition to hospice (1). While on treatment with SGLT2i, 11% of the patients were admitted with at least one episode of heart failure exacerbation and no reported mortality for the duration of follow-up. Conclusions Our experience suggests that long-term use of SGLT2i is well-tolerated in patients with ATTR-CA, even with renal dysfunction, and irrespective of LVEF. The side effects were comparable to that reported in other heart failure populations. It also demonstrated that patients did not have worse outcomes while receiving SGLT2i, and hospitalizations for heart failure exacerbation were seen only in a few of the patients. The effects of SGLT2i on morbidity and mortality in ATTR-CA warrant further exploration.

cardiac & cardiovascular systems